HC Wainwright Reiterates Neutral Rating for Kodiak Sciences (NASDAQ:KOD)

Kodiak Sciences (NASDAQ:KOD)‘s stock had its “neutral” rating restated by stock analysts at HC Wainwright in a report released on Monday,Benzinga reports. They presently have a $3.00 target price on the stock. HC Wainwright’s target price indicates a potential upside of 3.09% from the stock’s previous close.

Separately, Jefferies Financial Group raised shares of Kodiak Sciences from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research note on Monday, December 9th.

Kodiak Sciences Price Performance

KOD opened at $2.91 on Monday. The stock has a market capitalization of $153.14 million, a P/E ratio of -0.80 and a beta of 2.26. The company’s 50 day simple moving average is $4.85 and its 200-day simple moving average is $5.45. Kodiak Sciences has a one year low of $2.19 and a one year high of $11.60.

Kodiak Sciences (NASDAQ:KOD) last released its quarterly earnings data on Thursday, March 27th. The company reported ($0.84) EPS for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.06. As a group, analysts anticipate that Kodiak Sciences will post -3.45 EPS for the current year.

Hedge Funds Weigh In On Kodiak Sciences

Institutional investors have recently modified their holdings of the business. Barclays PLC lifted its stake in Kodiak Sciences by 65.5% in the third quarter. Barclays PLC now owns 79,658 shares of the company’s stock valued at $208,000 after buying an additional 31,527 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Kodiak Sciences by 220.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 44,648 shares of the company’s stock valued at $117,000 after purchasing an additional 30,735 shares during the period. FMR LLC lifted its holdings in shares of Kodiak Sciences by 26.4% in the third quarter. FMR LLC now owns 200,971 shares of the company’s stock valued at $525,000 after purchasing an additional 41,987 shares in the last quarter. State Street Corp boosted its position in shares of Kodiak Sciences by 1.8% during the third quarter. State Street Corp now owns 816,634 shares of the company’s stock worth $2,131,000 after buying an additional 14,711 shares during the period. Finally, Peapod Lane Capital LLC bought a new position in shares of Kodiak Sciences during the fourth quarter worth about $1,660,000. Institutional investors own 89.06% of the company’s stock.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.